Financial Performance - Total revenue for 2023 was CNY 166,949,828.23, a decrease of 22.74% compared to CNY 216,082,516.98 in the previous year[3] - Net profit attributable to shareholders was CNY 17,254,940.13, down 57.93% from CNY 41,013,230.25 year-on-year[3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 8,372,567.20, a decline of 77.22% compared to CNY 36,749,294.34 in the previous year[3] - Basic earnings per share decreased to CNY 0.25, down 67.76% from CNY 0.78 year-on-year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 450,591,887.38, an increase of 3.82% from CNY 433,992,572.72 at the beginning of the period[3] - Shareholders' equity attributable to the company was CNY 285,914,755.40, up 1.41% from CNY 281,951,875.27 at the beginning of the period[3] Revenue Breakdown - Revenue from food packaging equipment, which constitutes a significant portion of total revenue, decreased by 61.41% due to a downturn in the cheese industry[5] Margins and Expenses - Gross margin decreased by 14.10 percentage points, with food packaging equipment gross margin down 16.45 percentage points and pharmaceutical packaging equipment gross margin down 4.87 percentage points[5] - Selling expenses increased by 10.78% due to the recovery of international markets and exhibition activities[5] - Management expenses grew by 6.90% due to the establishment of new subsidiary operations[5]
春光药装(838810) - 2023 Q4 - 年度业绩